Cargando…

Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence

Anticoagulation with heparin and vitamin K antagonist has been the mainstay of prevention and treatment of venous thromboembolism (VTE) for many years. In recent years, novel oral anticoagulants such as dabigatran etexilate (a direct thrombin inhibitor) and rivaroxaban, apixaban, and edoxaban (a dir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zalpour, Ali, Oo, Thein Hlaing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226443/ https://www.ncbi.nlm.nih.gov/pubmed/25395835 http://dx.doi.org/10.2147/DDDT.S51006

Ejemplares similares

Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence
por: Zalpour, Ali, et al.
Publicado: (2015)

Prevention and Treatment of Venous Thromboembolism with New Oral Anticoagulants: A Practical Update for Clinicians
por: Tun, Nay Min, et al.
Publicado: (2013)

Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date
por: Trkulja, Vladimir
Publicado: (2016)

Extended Treatment with Apixaban for Venous Thromboembolism Prevention in the Netherlands: Clinical and Economic Effects
por: de Jong, Lisa A., et al.
Publicado: (2018)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice
por: Hendriks, Stephan V., et al.
Publicado: (2020)

Apixaban for treatment of venous thromboembolism in an obese patient with Glanzmann thrombasthenia
por: Sattler, Laurent, et al.
Publicado: (2023)

Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism
por: Reda, Sara, et al.
Publicado: (2022)

Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery
por: Werth, Sebastian, et al.
Publicado: (2012)

Apixaban/tocilizumab interaction: Venous thromboembolism: case report
Publicado: (2021)

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
por: Cornell, Robert Frank, et al.
Publicado: (2019)

Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
por: Weycker, Derek, et al.
Publicado: (2018)

Bleeding outcomes in thrombocytopenic acute leukemic patients with venous thromboembolism
por: Wilson, Nathaniel R., et al.
Publicado: (2020)

Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence
por: García-Escobar, I., et al.
Publicado: (2020)

Prevention and treatment of venous thromboembolism during HRT: current perspectives
por: Rott, Hannelore
Publicado: (2014)

Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
por: Weycker, Derek, et al.
Publicado: (2018)

Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United States
por: Deitelzweig, Steven, et al.
Publicado: (2018)

Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
por: Caroti, Kimberly Snow, et al.
Publicado: (2023)

Factor XI Inhibition for the Prevention of Venous Thromboembolism: An Update on Current Evidence and Future perspectives
por: Poenou, Geraldine, et al.
Publicado: (2022)

Venous Thromboembolism During Treatment with Antipsychotics: A Review of Current Evidence
por: Jönsson, Anna K., et al.
Publicado: (2018)

Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences
por: Lanitis, Tereza, et al.
Publicado: (2017)

Reducing the risk of venous thromboembolism using apixaban – patient perspectives and considerations. Should more attention be given to females?
por: Fabbian, Fabio, et al.
Publicado: (2016)

D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study
por: Palareti, Gualtiero, et al.
Publicado: (2022)

Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
por: Cohen, Alexander, et al.
Publicado: (2021)

Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
por: Cohen, Alexander T., et al.
Publicado: (2021)

Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis
por: Arce-Huamani, Miguel A., et al.
Publicado: (2023)

Venous Thromboembolism – Current Diagnostic and Treatment Modalities
por: Bosevski, Marijan, et al.
Publicado: (2016)

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism
por: McRae, Simon J, et al.
Publicado: (2005)

Prevention and treatment of venous thromboembolism in the elderly patient
por: Tincani, Enrico, et al.
Publicado: (2007)

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism
por: Kim, Joo Hee, et al.
Publicado: (2017)

Clinical characteristics and dosing of apixaban and rivaroxaban for the management of venous thromboembolism: A multi-center retrospective observational study
por: Al Yami, Majed S., et al.
Publicado: (2023)

Current status of treatment of cancer-associated venous thromboembolism
por: Xiong, Wei
Publicado: (2021)

Prevention and treatment of venous thromboembolism
por: Casadei, Barbara, et al.
Publicado: (2020)

Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure–Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism
por: Byon, W, et al.
Publicado: (2017)

Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry
por: Beyer-Westendorf, Jan, et al.
Publicado: (2021)

Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding
por: Cohen, Alexander T., et al.
Publicado: (2022)

Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences
por: Cohen, Alexander T., et al.
Publicado: (2023)

Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
por: Cohen, A. T., et al.
Publicado: (2016)

Current Challenges in Diagnosis of Venous Thromboembolism
por: Liederman, Zachary, et al.
Publicado: (2020)

Epidemiology and prevention of venous thromboembolism
por: Lutsey, Pamela L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4k967013cn4onsu297v869udr7